196-210 of 831
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
NeuroFrontiersVorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
Jennie Taylor, MD
Decoding CIDP: Pathogenesis, Diagnosis, and Clinical Clues
On the Frontlines of CIDPDecoding CIDP: Pathogenesis, Diagnosis, and Clinical Clues
Hans Katzberg, MD
Genetics in Schizophrenia Management: Emerging Technological Strategies
On the Frontlines of SchizophreniaGenetics in Schizophrenia Management: Emerging Technological Strategies
Aaron Besterman, MD
Understanding CIDP: A Roadmap to Diagnosis
On the Frontlines of CIDPUnderstanding CIDP: A Roadmap to Diagnosis
Sami Khella, MD
Evolving Strategies in CIDP Care: Personalized Approaches and Emerging Treatments
On the Frontlines of CIDPEvolving Strategies in CIDP Care: Personalized Approaches and Emerging Treatments
Sami Khella, MD
Investigating Gene Therapy for DMD: The Role of Caregiver-Reporter Scales
NeuroFrontiersInvestigating Gene Therapy for DMD: The Role of Caregiver-Reporter Scales
Craig M. McDonald, MD
- advertisement
Next Steps in Gene Therapy Research for Duchenne Muscular Dystrophy
NeuroFrontiersNext Steps in Gene Therapy Research for Duchenne Muscular Dystrophy
Craig M. McDonald, MD
Monitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels
NeuroFrontiersMonitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels
Engineering Autoimmunity: A New Model for Studying MS Progression and Remyelination
NeuroFrontiersEngineering Autoimmunity: A New Model for Studying MS Progression and Remyelination
Christian Cordano, MD, PhD
Advances in MS Management: Current and Future Directions
NeuroFrontiersAdvances in MS Management: Current and Future Directions
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
NeuroFrontiersDiagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
Nancy Kuntz, MD
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
NeuroFrontiersDuchenne Muscular Dystrophy Management: Analyzing Current Approaches
Nancy Kuntz, MD
- advertisement
From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia
NeuroFrontiersFrom Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia
Ashley Baker, MSN, PMHNP
Steven Paul, MD
Exploring Metabolomics in Multiple Sclerosis
NeuroFrontiersExploring Metabolomics in Multiple Sclerosis
Pavan Barghava, MD
Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response
NeuroFrontiersMetabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response
Pavan Barghava, MD
